BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Pharma Research

Asia-Pacific’s Geroscience Paradox: Plenty of Ageing Research, Just Five Clinical Assets

It is not a settled matter. It is a claim that has been made continuously for four years without anyone publishing the test they applied. So we wrote a tes...

August 12, 2026 | Analysis

HanchorBio Partners with Taiwan Cancer Moonshot Team to Advance Precision Immunotherapy

Collaboration connects internationally recognized cancer multi-omics research with HanchorBio's clinical-stage immuno-oncology platform to accelerate bioma...

August 11, 2026 | News

Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) eval...

August 11, 2026 | News

Forlong Biotechnology Completes Pivotal FL115 Manufacturing Milestone Ahead of Phase III NMIBC Trial

Forlong Biotechnology, a clinical-stage biotech company focused on developing transformative cytokine therapies for patients with severe unmet needs, today...

August 06, 2026 | News

From Market Access to Long-Term Growth: Rethinking Biopharma Expansion in APAC

BioPharma APAC speaks with Girisan Kariangal, Regional Vice President – Business Development & Alliance Management, Menarini Asia-Pacific, on the...

August 04, 2026 | Interaction

7 Manufacturing Technologies Moving From Pilot to Plant in APAC

HOW THE SEVEN WERE CHOSEN Inclusion required evidence of at least two commercial-scale installations in the region, with sites named wherever publ...

August 03, 2026 | Analysis

8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026

Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...

July 29, 2026 | Analysis

AsymBio Breaks Ground on Shanghai R&D Hub to Accelerate Biologics Development

AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.S...

July 29, 2026 | News

Tikva Allocell Raises $8M Series A to Advance Off-the-Shelf CAR-T Therapy for Solid Tumours

Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate targ...

July 24, 2026 | News

Nona Biosciences Partners with MedUni Vienna to Advance Fully Human Antibody Research

Partnership grants Ignaz Semmelweis Institute access to Nona's H2L2 Harbour Mice® transgenic mouse technology platform for translational antibody ...

July 24, 2026 | News

Lundbeck Completes Patient Randomisation in Phase III Bexicaserin Trial for Rare Epilepsies

DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse ...

July 22, 2026 | News

Merck Invests €25M to Expand BioReliance Testing Capabilities in Europe

• New 2,000-square-meter facility expands Merck’s global testing network with commercial drug substance and drug product release testing a...

July 17, 2026 | News

Evonik and evitria Simplify CHO-Based Protein Production with Ready-to-Use Expression Kit

New ready-to-use protein expression kit now available eviCHO Expression Kit simplifies transient protein expression workflows and enables faster, ...

July 17, 2026 | News

Australia Builds a New Radiopharmaceutical Gateway from Research to Patient Care

First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. Patient care...

July 17, 2026 | News

Stay Connected